Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 171

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 171
---
UVMI. Although ZELSUVMI has been approved by the FDA for the treatment of molluscum contagiosum in adult and pediatric patients one year of age and older, it may not achieve commercial success. The combined company has incurred, and expects to continue to incur, significant commercialization expenses related to the launch and product sales, marketing, distribution and manufacturing of ZELSUVMI as well as any future product candidates for which it receives regulatory approval. Following the Merger and the PIPE Financing, the combined company will also incur additional costs associated with operating as a public company. Based on its current operating plan, and assuming the Merger and the PIPE Financing are successfully completed, and assuming LNHC obtains at least $25 million in venture debt financing in connection with the closing of the Merger, LNHC believes that its existing cash, cash equivalents and short-term investments should be sufficient to fund its operations for at least one year after the consummation of the Merger. This estimate is based on assumptions that may prove to be materially wrong, and the combined company could use its available capital resources sooner than it currently expects. The combined company’s future capital requirements will depend on many factors, including:

| • | the progress and success of commercializing ZELSUVMI in the United States; |

| • | the number and development requirements of any product candidates that the combined company may pursue; |

| • | the number and scope of preclinical and clinical programs the combined company pursues; |

| • | the scope, progress, costs and results of the combined company’s development programs for other potential product candidates; |

| • | the extent to which the combined company develops, in-licenses or acquires products, product candidates or technologies; |

| • | the costs, timing and outcome of regulatory review of the combined company’s product candidates; |

| • | the revenue received from commercial sales of ZELSUVMI and any product candidates for which the combined company receives regulatory approval; |

94

TABLE OF CONTENTS

| • | the timing, receipt and terms of any regulatory approvals and any post-approval commitments from applicable regulatory authorities; |

| • | the extent to which the combined company establishes or maintains collaborations, strategic partnerships or other strategic arrangements with third parties, if any, and the performance of any third parties in connection therewith; |

| • | the impact of any business interruptions to its operations or to those of the third parties with whom the combined company works; and |

| • | the costs and timing of preparing